Clinical Edge Journal Scan

Weather Has a Limited Effect on PsA Symptoms


 

Key clinical point: In patients with psoriatic arthritis (PsA), disease activity was significantly lower in winter than in summer; however, the correlation between patient-reported outcomes (PROs) and weather-related factors lacked clinical significance.

Major finding: Disease activity scores, including the Clinical Disease Activity Index (mean, 8.2 vs 8.8; P < .001) and Simplified Disease Activity Index (mean, 8.6 vs 9.5; P < .001) scores, were significantly lower in winter than in summer. However, the association between weather-related factors and various PROs, including pain and fatigue measures, was not clinically significant (Pearson correlation coefficient, < 0.7).

Study details: In this study, 2665 PROs from 858 patients with PsA were analyzed and hourly measurements of temperature, relative humidity, and pressure were matched with disease activity and PROs in winter and summer.

Disclosures: The lead author received funding through the Canadian Association of Psoriasis Patients and the Canadian Institute of Health Research Institute of Musculoskeletal Health and Arthritis for this study. Some authors declared having ties with various sources.

Source: Joly-Chevrier M, Coupal L, Sauvageau LC, Movahedi M, Choquette D. A real-world analysis on weather variation disease activity and patient reported outcomes in psoriatic arthritis. J Rheumatol. Published online September 15, 2024. Source

Recommended Reading

Guselkumab Shows Early and Sustained Efficacy in PsA
MDedge Rheumatology
Bimekizumab Shows Long-Term Safety and Efficacy in Biologic-Naive and TNFi-IR PsA Patients
MDedge Rheumatology
Presence of Central Sensitization Should Be Considered During PsA Treatment
MDedge Rheumatology
Rheumatology Clinic Interventions for Smoking, Blood Pressure ‘Make a Big Difference’
MDedge Rheumatology
Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial Spondyloarthritis
MDedge Rheumatology
Commentary: PsA Targeted Therapy Trials, October 2024
MDedge Rheumatology
Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential Risks
MDedge Rheumatology
FDA Approves Ustekinumab Biosimilar Otulfi
MDedge Rheumatology
Rapid Improvement in Disease Activity With Ixekizumab vs IL-23 and IL-12/23 Inhibitors in PsA
MDedge Rheumatology
Bimekizumab Rapidly Improves Patient-Reported Outcomes in PsA
MDedge Rheumatology